Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 2, 2011, Pages 165-173

  Pang, Hui ^a   Cai, Li ^a   Yang, Yanmei ^a   Chen, Xuesong ^a   Sui, Guangjie ^a   Zhao, Changhong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

chemosensitivity; cyclophosphamide; MDA MB 231 cells; osteopontin; p38 MAPK pathway

Indexed keywords

CYCLOPHOSPHAMIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOPONTIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE KINASE KINASES; OSTEOPONTIN; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 79955886688     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0838     Document Type: Article

References (25)

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: Variations in epidemiology and survival. Clin Breast Cancer 2005;6:391.
2. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687.
3. Gillespie MT, Thomas RJ, Pu ZY, et al. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997;73:812.
4. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79:127.
5. Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001;171: 215.
6. Gu T, Ohashi R, Cui R, et al. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 2009;66:176.
7. Graessmann M, Berg B, Fuchs B, et al. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 2007;26:2840.
8. Reshkin SJ, Bellizzi A, Cardone RA, et al. Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na /H exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003;9:2366.
9. Cheng Y, Chang LW, Tsou TC. Mitogen-activated protein kinases mediate arsenic-induced down-regulation of surviving in human lung adenocarcinoma cells. Arch Toxicol 2006;80:310.
10. Deacon K, Mistry P, Chernoff J, et al. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic druginduced mitotic arrest. Mol Biol Cell 2003;14:2071.
11. Xing H, Cao Y, Weng D, et al. Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis 2008;13:213.
12. Shevde LA, Samant RS, Paik JC, et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB435. Clin Exp Metastasis 2006;23:123.
13. Yin BL, Hao H, Wang YY, et al. Downregulating osteopontin reduces angiotensin II-induced inflammatory activation in vascular smooth muscle cells. Inflamm Res 2009;58:67.
14. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994;78:539.
15. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807.
16. Losa JH, Parada Cobo C, Viniegra JG, et al. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003; 22:3998.
17. Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326.
18. Lenassi M, Plemenitaš A. The role of p38 MAP kinase in cancer cell apoptosis. Radiol Oncol 2006;40:51.
19. Pedraza-Alva G, Koulnis M, Charland C, et al. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J 2006;25:763.
20. Bulavin DV, Amundson SA, Fornace AJ. p38 and Chk1 kinases: Different conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev 2002;12:92.
21. Mikhailov A, Shinohara M, Rieder CL. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 2004;166:517.
22. Zhao J, Dong L, Lu B, et al. Down-regulation of osteopontin suppresses growth andmetastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008;135:956.
23. Lamour V, Le Mercier M, Lefranc F, et al. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 2009;126:1797.
24. Liu H, Chen A, Guo F, et al. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 2010;295:27.
25. Du XL, Jiang T, Sheng XG, et al. Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer. Gynecol Oncol 2009;115:371.